Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway

Toxicology and Applied Pharmacology

Volumn 251, Issue 2, 2011, Pages 130-136

  Luo, Qiong ^a   Gu, Yanhong ^b   Zheng, Wei ^a   Wu, Xingxin ^a   Gong, Fangyuan ^a   Gu, Liyun ^a   Sun, Yang ^a   Xu, Qiang ^a  

^a NANJING UNIVERSITY   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Akt; C Raf ERK; Erlotinib; Immunosuppression; T cells

Indexed keywords

CD3 ANTIBODY; CONCANAVALIN A; ERLOTINIB; GAMMA INTERFERON; INTERLEUKIN 12; MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL MYRISTATE; RAF PROTEIN; STAPHYLOCOCCUS ENTEROTOXIN B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTACT DERMATITIS; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; HEAD AND NECK CARCINOMA; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; ONCOGENE PROTEIN V-AKT; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RAF; QUINAZOLINES; T-LYMPHOCYTE SUBSETS;

EID: 79851514063     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2010.12.011     Document Type: Article

References (42)

1. Akita R.W., Sliwkowski M.X. Preclinical studies with erlotinib (Tarceva). Semin. Oncol. 2003, 30(3):15-24.
2. Aktas H., Cai H., Cooper G.M. Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27(KIP1). Mol. Cell. Biol. 1997, 17(7):3850-3857.
3. Bareschino M.A., Schettino C., Troiani T., Martinelli E., Morgillo F., Ciardiello F. Erlotinib in cancer treatment. Ann. Oncol. 2007, 18:35-41.
4. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411(6835):355-365.
5. Bovenschen H.J., Alkemade J. Erlotinib-induced dermatologic side-effects. Int. J. Dermatol. 2009, 48(3):326-328.
6. Chou L.S., Garey J., Oishi K., Kim E. Managing dermatologic toxicities of epidermal growth factor receptor inhibitors. Clin. Lung Cancer 2006, 8:S15-S22.
7. Ciardiello F., Tortora G. Drug therapy: EGFR antagonists in cancer treatment. N. Engl. J. Med. 2008, 358(11):1160-1174.
8. Comis R.L. The current situation: Erlotinib (Tarceva (R)) and gefitinib (Iressa (R)) in non-small cell lung cancer. Oncologist 2005, 10(7):467-470.
9. Czyzyk J., Chen H.C., Bottomly K., Flavell R.A. p21 Ras/impedes mitogenic signal propagation regulates cytokine production and migration in CD4 T cells. J. Biol. Chem. 2008, 283(34):23004-23015.
10. Gollob J.A., Wilhelm S., Carter C., Kelley S.L. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin. Oncol. 2006, 33(4):392-406.
11. Gridelli C., Rossi A., Malone P., Colantuoni G., Del Gaizo F., Ferrara C., Nicolella D., Guerriero C. Erlotinib in non-small-cell lung cancer. Expert Opin. Pharmacother. 2007, 8(15):2579-2592.
12. Hamilton M., Wolf J.L., Rusk J., Beard S.E., Clark G.M., Witt K., Cagnoni P.J. Effects of smoking on the pharmacokinetics of erlotinib. Clin. Cancer Res. 2006, 12(7 Pt 1):2166-2171.
13. Hidalgo M., Bloedow D. Pharmacokinetics and pharmacodynamics: maximizing the clinical potential of erlotinib (Tarceva). Semin. Oncol. 2003, 30(3):25-33.
14. Hynes N.E., Lane H.A. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat. Rev. Cancer 2005, 5(5):341-354.
15. Lea N.C., Orr S.J., Stoeber K., Williams G.H., Lam E.W., Ibrahim M.A., Mufti G.J., Thomas N.S. Commitment point during G0->G1 that controls entry into the cell cycle. Mol. Cell. Biol. 2003, 23(7):2351-2361.
16. Li Z., Xu M., Xing S., Ho W.T., Ishii T., Li Q., Fu X., Zhao Z.J. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth. J. Biol. Chem. 2007, 282(6):3428-3432.
17. Li M., Ong S.S., Rajwa B., Thieu V.T., Geahlen R.L., Harrison M.L. The SH3 domain of Lck modulates T cell receptor-dependent activation of extracellular signal-regulated kinase through activation of Raf-1. Mol. Cell. Biol. 2008, 28(2):630-641.
18. Li X., Kamenecka T.M., Cameron M.D. Cytochrome P450-mediated bioactivation of the epidermal growth factor receptor inhibitor erlotinib to a reactive electrophile. Drug Metab. Dispos. 2010, 38(7):1238-1245.
19. Ling J., Johnson K.A., Miao Z., Rakhit A., Pantze M.P., Hamilton M., Lum B.L., Prakash C. Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers. Drug Metab. Dispos. 2006, 34(3):420-426.
20. Ling Y.H., Li T., Yuan Z., Haigentz M., Weber T.K., Perez-Soler R. Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines. Mol. Pharmacol. 2007, 72(2):248-258.
21. Liu V., White D.A., Zakowski M.F., Travis W., Kris M.G., Ginsberg M.S., Miller V.A., Azzoli C.G. Pulmonary toxicity associated with erlotinib. Chest 2007, 132(3):1042-1044.
22. Liu W.T., Makrauer F.L., Qamar A.A., Janne P.A., Odze R.D. Fulminant hepatic failure secondary to erlotinib. Clin. Gastroenterol. Hepatol. 2007, 5(8):917-920.
23. Lubbe J., Masouye I., Dietrich P.Y. Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva (R)). Dermatology 2008, 216(3):247-249.
24. Makris D., Scherpereel A., Copin M.C., Colin G., Brun L., Lafitte J.J., Marquette C.H. Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer 2007, 7:4.
25. McCubrey J.A., Steelman L.S., Abrams S.L., Lee J.T., Chang F., Bertrand F.E., Navolanic P.M., Terrian D.M., Franklin R.A., D'Assoro A.B., Salisbury J.L., Mazzarino M.C., Stivala F., Libra M. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul. 2006, 46:249-279.
26. Ocana A., Serrano R., Calero R., Pandiella A. Novel tyrosine kinase inhibitors in the treatment of cancer. Curr. Drug Targets 2009, 10(6):575-576.
27. Onn A., Correa A.M., Gilcrease M., Isobe T., Massarelli E., Bucana C.D., O'Reilly M.S., Hong W.K., Fidler I.J., Putnam J.B., Herbst R.S. Synchronous overexpression of epidermal growth factor receptor and HER2-neu protein is a predictor of poor outcome in patients with stage I non-small cell lung cancer. Clin. Cancer Res. 2004, 10(1):136-143.
28. O'Shea J.J., Pesu M., Borie D.C., Changelian P.S. A new modality for immunosuppression: targeting the JAK/STAT pathway. Nat. Rev. Drug Discov. 2004, 3(7):555-564.
29. Pellegrinotti M., Fimognari F.L., Franco A., Repetto L., Pastorelli R. Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer. Ann. Pharmacother. 2009, 43(3):542-545.
30. Perez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) in non-small-cell lung cancer. Clin. Lung Cancer 2004, 6(Suppl 1):S20-S23.
31. Pollack V.A., Savage D.M., Baker D.A., Tsaparikos K.E., Sloan D.E., Moyer J.D., Barbacci E.G., Pustilnik L.R., Smolarek T.A., Davis J.A., Vaidya M.P., Arnold L.D., Doty J.L., Iwata K.K., Morin M.J. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358, 774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther. 1999, 291(2):739-748.
32. Prados M.D., Lamborn K.R., Chang S., Burton E., Butowski N., Malec M., Kapadia A., Rabbitt J., Page M.S., Fedoroff A., Xie D., Kelley S.K. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol. 2006, 8(1):67-78.
33. Saif M.W. Erlotinib-induced acute hepatitis in a patient with pancreatic cancer. Clin. Adv. Hematol. Oncol. 2008, 6(3):191-199.
34. Shepherd F.A., Pereira J.R., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., Campos D., Maoleekoonpiroj S., Smylie M., Martins R., van Kooten M., Dediu M., Findlay B., Tu D.S., Johnston D., Bezjak A., Clark G., Santabarbara P., Seymour L. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005, 353(2):123-132. Natl Canc Inst Canada Clin T.
35. Siegel-Lakhai W.S., Beijnen J.H., Schellens J.H.M. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva (R)) and gefitinib (Iressa (R)). Oncologist 2005, 10(8):579-589.
36. Sun Y., Qin Y., Gong F.Y., Wu X.F., Hua Z.C., Chen T., Xu Q. Selective triggering of apoptosis of concanavalin A-activated T cells by fraxinellone for the treatment of T-cell-dependent hepatitis in mice. Biochem. Pharmacol. 2009, 77(11):1717-1724.
37. Sun Y., Wu X.X., Yin Y., Gong F.Y., Shen Y., Cai T.T., Zhou X.B., Wu X.F., Xu Q. Novel immunomodulatory properties of cirsilineol through selective inhibition of IFN-gamma signaling in a murine model of inflammatory bowel disease. Biochem. Pharmacol. 2010, 79(2):229-238.
38. Tang P.A., Tsao M.S., Moore M.J. A review of erlotinib and its clinical use. Expert Opin. Pharmacother. 2006, 7(2):177-193.
39. Tiseo M., Gridelli C., Cascinu S., Crino L., Piantedosi F.V., Grossi F., Brandes A.A., Labianca R., Siena S., Amoroso D., Belvedere O., Valentino B., Bearz A., Venturino P., Ardizzoni A. An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): Data report from Italy. Lung Cancer 2009, 64(2):199-206.
40. Wong K.Y.M., Lo A., Lam J., Lam B., Ip M.S., Ho J.C. Erlotinib as salvage treatment after failure to first-line gefitinib in Non-Small Cell Lung Cancer. Cancer Chemother. Pharmacol. 2009, 65(6):1023-1028.
41. Xue L., Chiang L., Kang C., Winoto A. The role of the PI3K-AKT kinase pathway in T cell development beyond the beta checkpoint. Eur. J. Immunol. 2008, 38(11):3200-3207.
42. Zhang Y., Miao J.Y., Hanley G., Stuart C., Sun X.L., Chen T.T., Yin D.L. Chronic restraint stress promotes immune suppression through Toll-like receptor 4-mediated phosphoinositide 3-kinase signaling. J. Neuroimmunol. 2008, 204(1-2):13-19.